Press Release November 30, 2017

Semma Therapeutics Completes $114 Million Series B Financing Round

The Life Sciences team advised Semma Therapeutics on the completion of its highly oversubscribed $114 million Series B financing round. Proceeds will be used to bring Semma’s lead development program, encapsulated stem cell-derived islets, through clinical proof-of-concept in patients and to continue exploration of other regenerative medicine therapeutics. Eight Roads Ventures and Cowen Healthcare Investments co-led the financing with significant investments from all existing investors including MPM Capital, F-Prime Capital Partners and ARCH Venture Partners, existing strategic partners Novartis, Medtronic and the JDRF T1D Fund, and new investors including ORI Healthcare Fund, Wu Capital, 6 Dimensions Capital and SinoPharm Capital.

Semma Therapeutics is a regenerative medicine company founded to develop transformative stem cell-derived therapies.

The Goodwin team was led by partners Kingsley Taft and Caitlin Murray and associates Riley Lovendale and Stephen Fox; and included paralegal Kathryn Georgian.

For additional details on the financing, please read the press release.